Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab with trastuzumab and chemotherapy in HER2-positive advanced gastric cancer
NL-OMON35408Phase 2Withdrawn
- Sponsor
- Roche
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pertuzumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Roche. Planned start Sep 2011; status: withdrawn.
02
Drugs
pertuzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON35408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35408.